All In Biotech

Drug Trial Radar · NCT01903109

Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions

A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions

Last checked: Nov 20, 2026Latest source record: Jan 23, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

27

Actual

Start

Feb 2009

Primary completion

Feb 2009

Study completion Feb 2009

Sponsor

Lead sponsor
Roxane LaboratoriesIndustry
Sponsor type
Industry
First posted
Jul 19, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fed conditions

Conditions

  • Dry Mouth

Interventions

  • CevimelineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. bioequivalence determined by statistical comparison CmaxTime frame: 33 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novum Pharmaceutical Research Services

    Las Vegas, Nevada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.